GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Acyclovir

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The original page contains two different IV renal band sets (25/50 versus 30/50) and an indexed CrCl table. They are preserved separately, not reconciled into one recommendation. Confirm the applicable current product label before clinical use.

Check source scope before reading a dose

UCSF - acyclovir intravenous: HSV, VZV and dialysis

Product / population
Adults; IV acyclovir only. Separate from oral and topical formulations.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional

UCSF - acyclovir intravenous: HSV, VZV and dialysis

Open original reference

UCSF Infectious Diseases Management Program · Adults; IV acyclovir only. Separate from oral and topical formulations.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

The printed bands overlap at exactly 25. Do not choose a boundary by assumption.

UCSF uses actual weight unless above 120% of ideal, then adjusted weight; this differs from ideal-weight labeling in obesity. These are IV regimens. Reassess dialysis prescription and residual function.

Non-CNS HSV - IV
CrCl, mL/minSource-specific dose / instruction
>505 mg/kg every 8 hours
25-505 mg/kg every 12 hours
10-255 mg/kg every 24 hours
<102.5 mg/kg every 24 hours
Encephalitis or disseminated VZV - IV
CrCl, mL/minSource-specific dose / instruction
>5010 mg/kg every 8 hours
25-5010 mg/kg every 12 hours
10-2510 mg/kg every 24 hours
<105 mg/kg every 24 hours
Dialysis guidance - separate source-specific schedules
IV acyclovir - dialysis
Dialysis setting / indicationSource-specific schedule
Intermittent HD - non-CNS HSV2.5 mg/kg initially and each evening
Intermittent HD - encephalitis/disseminated VZV5 mg/kg initially and each evening
Continuous HD - non-CNS HSV5 mg/kg every 24 hours
Continuous HD - encephalitis/disseminated VZV10 mg/kg every 12 hours
Read the retained text before reformatting

CrCl >50 / 25-50 / 10-25 / <10 mL/min: non-CNS HSV uses 5 mg/kg IV every 8 / 12 / 24 hours, then 2.5 mg/kg daily in the lowest band. Encephalitis or disseminated VZV uses 10 mg/kg every 8 / 12 / 24 hours, then 5 mg/kg daily. The source overlaps at exactly 25.

Intermittent HD: non-CNS HSV 2.5 mg/kg initially and each evening; encephalitis/disseminated VZV 5 mg/kg initially and each evening. Continuous HD: non-CNS HSV 5 mg/kg daily; encephalitis/disseminated VZV 10 mg/kg every 12 hours.

UCSF uses actual weight unless above 120% of ideal, then adjusted weight; its discussion acknowledges disagreement with ideal-weight labeling for obesity. These are institutional IV regimens, not oral dosing. Dialysis prescription and residual function can materially change requirements.

RDM30-033-acyclovir-1 · Source locator: UCSF - acyclovir intravenous: HSV, VZV and dialysis; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/acyclovir-iv
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
61d7d1340be3d6cc8b1efd4632bea4d0f6a1bfa238a168afd8ed36485114830f

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=acyclovir&s1=RDM30-033-acyclovir&h1=7ce092b01793e44936b5c5a74807f21d61cd26fe0d0a3d9d9a5bb20260381b2d